-
2024-514108-15-00
4
Allergies
-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2025-520471-29-00
5
Locally advanced adenocarcinoma of the colon and upper rectum with mic
-
2025-521221-32-00
5
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2025-521230-29-00
5
Allergic rhinoconjunctivitis to Dermatophagoides pteronyssinus and Der
-
2025-521301-40-00
6
Prevention of new morphometric vertebral fractures and/or worsening of
-
2025-521709-42-00
5
Allergic rhinoconjunctivitis with or without asthma due to clinically
-
2025-521736-10-00
5
Allergic rhinoconjunctivitis with or without controlled asthma
-
2025-522471-28-00
5
psoriatic arthritis (PsA)
-
2025-525013-23-00
4
Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)
-
2025-522255-25-00
5
2026-05-18
Fallopian Tube Neoplasms
-
2023-505661-89-00
4
2025-12-19
Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F
-
2024-510778-26-00
4
2025-12-19
Metastatic Non-Small-Cell Lung Cancer
-
2024-518131-11-02
4
2025-01-24
Localised Colon Cancer (stage II-III)
-
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
-
2023-505606-42-00
5
2024-10-15
Head and Neck Squamous Cell Carcinoma (HNSCC)
-
2022-500273-14-00
10
2023-07-17
Atherosclerotic cardiovascular disease in patients with ESKD
-
2025-522979-29-00
5
2026-04-30
Acute myeloid leukemia
-
2025-523119-12-00
10
2026-04-02
Patients with moderate-to-severe allergic rhinitis / rhinoconjunctivit
-
2024-515765-34-00
5
2026-02-04
English
First-line extensive-stage small-cell lung cancer (ES-SCLC)
-
2024-515658-26-00
5
2026-01-21
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
-
2024-519493-39-00
5
2025-12-09
High-risk Non-muscle-invasive Bladder
Cancer with Susceptible FGFR Alt
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2025-521522-15-00
4
2025-11-05
Allergic rhinitis/rhinoconjunctivitis caused by dust mite allergy